Considering the current limitations of EEF2K inhibitors for clinical application, we screened the US FDA‐approved drug library for antitumour compounds and identified cytarabine as a potential clinically applicable EEF2K inhibitor that has a synergistic effect with BET inhibitors in melanoma treatment. The gene discussed is EEF2K; the disease is melanoma.